Kaposi's sarcoma (KS) was first described in 1872 as a rare vascular
tumor characterized by multiple skin nodules of the lower extremity,
which was seen primarily in older men of eastern European or Mediterranean
descent . The tumor rarely involved visceral organs and generally
had an indolent course. A more virulent, endemic form of KS was
subsequently described in sub-Saharan Africa and involved younger
men with cutaneous, lymphatic, and visceral involvement. It ran
a more aggressive clinical course. Yet another group of non-HIV-infected
patients with KS were those who received immunosuppressive therapy
for organ transplantation or an autoimmune disease and in whom
occasional spontaneous regression of lesions had been reported
with withdrawal of immunosuppressive therapy. These various KS-affected
populations suggested possible genetic, infectious, and immunologic
underpinnings to the development of these tumors .
The recognition of KS in US male homosexuals in the early 1980s
heralded the AIDS epidemic . Early descriptions of AIDS suggested
that as many as 50% of gay men with T-cell immune deficiency developed
KS as one of their manifestations of AIDS. The proportion of patients
with KS as the initial manifestation of AIDS has declined to approximately
11% in 1991 [4,5]. Several characteristics of this tumor, including
its more aggressive clinical course; frequent involvement of lymph
nodes, gastrointestinal tract, lung, and other viscera; and its
almost exclusive early occurrence in the gay male AIDS population
with other evidence of immune deficiency suggested that this tumor
was more akin to the African variant of KS and likely was associated
with a sexually transmitted agent.
An additional feature of AIDS-related KS (AIDS/KS) that must be
explained in any model of pathogenesis includes the fact that
approximately 90% of AIDS/KS cases in the United States occur
in homosexual men, and far fewer cases have been seen in women,
intravenous drug users, or heterosexual males. Kaposi's sarcoma
has also been described in homosexual males who are not HIV-infected
. While the number of HIV-infected women is lower than the
number of men, the frequency of KS in women is relatively high
in Africa and in women in western countries who have had sex with
bisexual men, compared to those whose sexual partners are heterosexuals
or intravenous drug users (3% vs 0.7%) .
These findings suggest that a sexually transmitted infectious
agent likely is involved in the pathogenesis of KS and that this
agent is more prevalent in US gay men and the general African
population. The findings also suggest that androgens or other
male factors may facilitate the development of this tumor.
The declining incidence of KS in the gay male population in the
mid- to late 1980s as a result of increased awareness of HIV and
the more widespread use of safe sex practices led to speculation
that sexually transmitted infections may be associated with the
development of this tumor. Declining incidence of cytomegalovirus
(CMV) seropositivity in association with declining occurrence
of KS led to speculation of a potential role for this virus in
KS pathogenesis [8,9]. Cytomegalovirus was not consistently detected
by in situ hybridization or other methods in KS tissue, however,
and the widespread prevalence of this virus in AIDS patients who
do not have KS argue against the involvement of CMV in KS tumor
There also has been speculation about the potential role that
other DNA viruses, such as an Epstein Barr-like virus (EBV) 
and the human papilloma virus (HPV), may play in the pathogenesis
of KS . However, the fact these viral sequences have not uniformly
been found in KS tumors suggests that infection with these viruses
may be more coincidental than causative for KS. No clear evidence
of the involvement of CMV, EBV, or HPV in the development of KS
has yet been established.
Recently, using representational difference analyses, Chang and
Moore have identified sequences of a unique gamma human herpesvirus,
termed the KS-associated herpesvirus (KSHV), in high frequency
in KS tissues from patients with AIDS . These viral
sequences, somewhat homologous to sequences of the herpes saimiri
virus, which can induce lymphoma in monkeys, have been identified
in more than 90% of KS biopsies from HIV-infected and uninfected
individuals but not in uninvolved tissues from the same patients
or from normal controls [14-16].
Sequences of KSHV also have been found in an unusual variant of
non-Hodgkin's lymphoma in patients with AIDS (ie, body cavity
lymphomas), in association with EBV . However, the recent
finding of KSHV-like sequences in patients with other dermatologic
disorders and the loss of these particles in multiple passaged
KS cell lines raises the possibility that this virus could be
a passenger virus rather than a directly transforming one .
Determination of the exact role of KSHV in the pathogenesis of
KS will require viral isolation and further characterization of
the direct and indirect effects of this virus. However, detection
of KSHV sequences in high frequency and specificity in patients
with KS has led to renewed interest in the role of viruses in
the development of tumors in the setting of immunosuppression
and in the possible use of viral inhibitory agents in controlling
tumor development and growth.
Lesions of KS vary considerably in their clinical presentation
and, to a lesser degree, in their histologic appearance. These
lesions can involve predominantly the skin and oral mucosa, as
well as a number of visceral organs, and can range in appearance
from pink or red macules to dark blue and purple papules or nodules.
Histologically, KS lesions are characterized by intense neovascularization
and the appearance of spindle cells, which are considered to be
the tumor cells of KS. The spindle cells proliferate among characteristic
slit-like spaces produced by the aberrant vascular structures.
These cells have a low mitotic index and are euploid [19,20].
Fibroblasts, extravasated red blood cells, and inflammatory cells
are mixed in with the spindle cells. The histologic characteristics
of early and advanced KS differ in that the spindle cells in advanced
lesions are more abundant and form more compact masses.
The origin of the spindle cells is somewhat controversial, as
these cells share several histologic features with various other
types of cells . Immunohistochemically, spindle cells are
somewhat similar to endothelial cells in that they stain with
Ulex europaeus and are negative to factor VIII and EN-4
. A mesenchymal origin is suggested by the presence of alpha-actin,
a smooth muscle marker, and shared positivity with the hematopoietic
cell markers CD34 and CD18 . It is currently believed that
KS most likely is of mesenchymal origin, possibly a smooth muscle
progenitor, with multiphenotypic markings reflective of early
differentiation or transformation.
1. Kaposi M: Idiopathic multiples Pigmentsarcom der Haut. Arch
Dermatol Syph 4:265-274, 1872 (English translation, A Cancer Journal
for Clinicians 32:342-347, 1982).
2. Rabkin CS: Epidemiology of AIDS-related malignancies. Curr
Opin Oncol 6:492-496, 1994.
3. Friedman-Kein A, Laubenstein L, Marmor M, et al: Kaposi's sarcoma
and Pneumocystis pneumonia among homosexual men. Morbid Mortal
Weekly Rep 30:305, 1981.
4. Armenian HK, Hoover DR, Rubb S, et al: Composite risk score
for Kaposi's sarcoma based on a case-control and longitudinal
study in the Multicenter AIDS Cohort Study (MACS) population.
Am J Epidemiol 138:256-265, 1993.
5. Gallant JE, Moore RD, Richman DD, et al: Risk factors for Kaposi's
sarcoma in patients with advanced human immunodeficiency virus
disease treated with zidovudine: Zidovudine epidemiology study
group. Arch Intern Med 154:566-572, 1994.
6. Friedman-Kien AE, Saltzman BR, Cao Y, et al: Kaposi's sarcoma
in HIV negative homosexual men. Lancet 1:168-169, 1990.
7. Lassoued K, Clauvel JJ, Fegueux S, et al: AIDS-associated Kaposi's
sarcoma in female patients. AIDS 5:877-880, 1991.
8. Johnston GC, Jockusch J, McMurtry LC, et al: Cytomegalovirus
(CMV) titers among acquired immunodeficiency syndrome (AIDS) patients
with and without a history of Kaposi's sarcoma (KS). Cancer Detect
Prevent 14:337-342, 1990.
9. Drew WL, Mills J, Hauer LB, et al: Declining prevalence of
Kaposi's sarcoma in homosexual AIDS patients paralleled by fall
in cytomegalovirus transmission. Lancet 1:66, 1988.
10. Andersen GB, Karkov J, Bjerregaard B, et al: Cytomegalovirus
infection in classic endemic and epidemic Kaposi's sarcoma analyzed
by in situ hybridization. APMIS 99:893-897, 1991.
11. Rappersberger K, Tscachler E, Zonzits E, et al: Endemic Kaposi's
sarcoma in HIV-1 seronegative persons: Demonstration of retrovirus
like particles in cutaneous lesions. J Invest Dermatol 95:371-381,
12. Huang YQ, Li JJ, Rush MG, et al: HPV-16 related DNA sequences
in Kaposi's sarcoma. Lancet 339:515-518, 1992.
13. Chang Y, Cesarman E, Pessin MS, et al: Identification of herpes
virus-like DNA sequences in AIDS-associated Kaposi's sarcoma.
Science 266:1865-1869, 1994.
14. Moore PS, Chang Y: Detection of herpes virus-like DNA sequences
in Kaposi's sarcoma in patients with and without HIV infection.
N Engl J Med 332:1181-1185, 1995.
15. Huang YQ, Li JJ, Kaplan MH, et al: Human herpes virus-like
nucleic acid in various forms of Kaposi's sarcoma. Lancet 345:759-761,
16. Dupin N, Grandadam M, Calvez V, et al: Herpes virus-like DNA
sequences in patients with Mediterranean Kaposi's sarcoma. Lancet
17. Cesarman E, Chang Y, Moore PS, et al: Kaposi's sarcoma-associated
herpes virus-like DNA sequences in AIDS-related body-cavity-based
lymphomas. N Engl J Med 332:1186-1191, 1995.
18. Rady PL, Yen A, Rollefson JL, et al: Herpes virus-like DNA
sequences in non-Kaposi's sarcoma skin lesions of transplant patients.
Lancet 345:1339-1340, 1995.
19. Mitsuyasu RT: Kaposi's sarcoma in the acquired immunodeficiency
syndrome. Infect Dis Clin North Am 2:511-523, 1989.
20. Gottlieb GJ, Ackerman AB: Kaposi's Sarcoma: A Text and Atlas.
Philadelphia, Lea and Feiger, 1988.
21. Kaul A, Pearson JD, Petty R, et al: Vascular epithelium: A
potential role in HIV infection and the pathogenesis of Kaposi's
sarcoma. Mol Aspects Med 12:297-312, 1991.
22. Ensoli B, Barillari G, Gallo RC: Pathogenesis of AIDS-associated
Kaposi's sarcoma. Hematol Oncol Clin North Am 5(2):281-295, 1991.
23. Weich HA, Salahuddin SZ, Gill P, et al: AIDS-associated Kaposi's
sarcoma-derived cells in long-term culture express and synthesize
smooth muscle alpha-actin. Am J Pathol 139:1251-1258, 1991.
24. Nakamura S, Salahuddin SZ, Biberfeld P, et al: Kaposi's sarcoma
cells: Long-term culture with growth factor from retrovirus-infected
CD4+ T cells. Science 242:426-430, 1988.
25. Miles SA: Pathogenesis of HIV-related Kaposi's sarcoma. Curr
Opin Oncol 6:497-502, 1994.
26. Salahuddin SZ, Nakamura S, Biberfeld P, et al: Angiogenic
properties of Kaposi's sarcoma-derived cells after long-term culture
in vitro. Science 242:430-433, 1988.
27. Ensoli B, Salahuddin SZ, Gallo RC: AIDS-associated Kaposi's
sarcoma: A molecular model for its pathogenesis. Cancer Cells
28. Ensoli B, Barillari G, Gallo RC: Cytokines and growth factors
in the pathogenesis of AIDS-associated Kaposi's sarcoma. Immunol
Rev 127:147-155, 1992.
29. Barillari G, Buonaguro L, Fiorelli V, et al: Effects of cytokines
from activated immune cells on vascular cell growth and HIV-1
gene expression: Implications for AIDS-Kaposi's sarcoma pathogenesis.
J Immunol 149:3727-3734, 1992.
30. Roth WK: TGF beta and FGF-like growth factors involved in
the pathogenesis of AIDS-associated Kaposi's sarcoma. Res Virol
31. Miles SA: Kaposi's sarcoma, in Benz CC and Liu ET (eds): A
cytokine responsive neoplasia, in Oncogenes and Tumor Suppressor
Genes in Human Malignancies, pp 129-140. Boston, Kluwer Academic
32. Nair BC, Devico AL, Nakamura S, et al: Identification of a
major growth factor for AIDS-Kaposi's sarcoma cells as oncostatin
M. Science 255:1430-1432, 1992.
33. Miles SA, Martinez-Maza O, Rezai A, et al: Oncostatin M as
a potent mitogen for AIDS-Kaposi's sarcoma-derived cells. Science
34. Huang YQ, Li JJ, Kim KS, et al: HIV-1 infection and modulation
of cytokine and growth factor expression in Kaposi's sarcoma-derived
cells in vitro. AIDS 7:317-322, 1993.
35. Ensoli B, Nakamura S, Saluhuddin SZ, et al: AIDS-Kaposi's
sarcoma-derived cells express cytokines with autocrine and paracrine
growth effects. Science 243:223-226, 1989.
36. Sturzl M, Willi KR, Brockmeyer NH, et al: Expression of PDGF
and its receptor in AIDS-related KS in vivo suggests paracrine
and autocrine mechanisms of tumor maintenance. Proc Natl Acad
Sci USA, 89:7046-7050, 1992.
37. Vogel J, Hinrichs SH, Reynolds RK, et al: The HIV tat gene
induces dermal lesions resembling Kaposi's sarcoma in transgenic
mice. Nature 335:606-611, 1988.
38. Ensoli B, Barillari G, Salahuddin SZ, et al: Tat protein of
HIV-1 stimulates growth of cells derived from Kaposi's sarcoma
lesions of AIDS patients. Nature 345:84-86, 1990.
39. Ensoli B, Buonaguro L, Barillari G, et al: Release and uptake,
and effects of extracellular human immunodeficiency virus type
I tat protein on cell growth and viral transactivation. J Virol
40. Miles SA, Rezai AR, Salazar-Gonzalez JF, et al: AIDS Kaposi's
sarcoma-derived cells produce and respond to IL-6. Proc Natl Acad
Sci USA 87:4068-4072, 1990.
41. Motro B, Itin A, Sachs L, et al: Pattern of interleukin-6
gene expression in vivo suggests a role of this cytokine in angiogenesis.
Proc Natl Acad Sci USA 87:3092-3096, 1990.
42. Gearing DP, Comeau MR, Friend DJ, et al: The IL-6 signal transducer,
gp130: An oncostatin M receptor and affinity converter for the
LIF receptor. Science 255:1434-1437, 1992.
43. Martinez-Maza O, Dourado I, Kishimoto T, et al: Elevated serum
IL-6 levels are associated with the development of AIDS-KS (abstract).
Ninth International Conference on AIDS, vol 1, p 397, 1993.
44. De Wit R, Raasveld MHM, Ten Berge RJM, et al: Il-6 concentrations
in the serum of patients with AIDS-associated Kaposi's sarcoma
during treatment with interferon alpha. J Intern Med 229:539-542,
45. Sidky YA, Borden EC: Inhibition of angiogenesis by interferons:
Effects on tumor- and lymphocyte-induced vascular responses. Cancer
Res 47:5155-5161, 1987.
46. Browning PJ, Roberts DD, Zabrenetsky V, et al: Apolipoprotein
E (ApoE), a novel heparin-binding protein inhibits the development
of Kaposi's sarcoma-like lesions in BALB/c nu/nu mice. J Exp Med
47. Sinkovics JG: Kaposi's sarcoma: Its "oncogenes"
and growth factors. Crit Rev Oncol Hematol, 11:87-107, 1991.
48. Huang YQ, Li JJ, Moscatelli D, et al: Expression of Int-2
oncogene in KS lesions. J Clin Invest 91:1191-1197, 1993.
49. McGrath MS, Shiramizu BT, Hernider BG: Identification of a
clonal form of HIV in early Kaposi's sarcoma: Evidence for a novel
model of oncogenesis, "sequential neoplasia." J Acquir
Immune Defic Syndr Hum Retrovirol 8:379-385, 1995.
50. Gill PS, Louriero C, Bernstein-Singer M, et al: Clinical effect
of Glucocorticoids on Kaposi's sarcoma related to AIDS. Ann Intern
Med 110:937-940, 1989.
51. Christeff N, Winter C, Gharakhanian S, et al: Androgens of
HIV positive patients with or without Kaposi's sarcoma. J Clin
Path, 48:513-518, 1995.
52. Corallini A, Altavilla G, Pozzi L, et al: Systemic expression
of HIV-1 tat gene in transgenic mice induces endothelial proliferation
and tumors of different histotypes. Cancer Res 53:5569-5575, 1993.
53. Herndier BG, Werner A, Arnstein P, et al: Characterization
of a human Kaposi's sarcoma cell line that induces angiogenic
tumors in animals. AIDS 8:575-581, 1994.
54. Lunardi-Iskandar Y, Bryant JL, Zeman RA, et al: Tumorigenesis
and metastasis of neoplastic Kaposi's sarcoma cell line in immunodeficient
mice blocked by a human pregnancy hormone. Nature 375: 64-68,
55. Harris PJ: Treatment of Kaposi's sarcoma and other manifestations
of AIDS with human chorionic gonadotropin. Lancet 346:118-119,